On August 6, 2025, Assembly Biosciences, Inc. announced its financial results for Q2 2025 and shared interim results from a clinical study of ABI-6250, a hepatitis delta virus treatment.
AI Assistant
ASSEMBLY BIOSCIENCES INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.